Basu Partha, Ponti Antonio, Anttila Ahti, Ronco Guglielmo, Senore Carlo, Vale Diama Bhadra, Segnan Nereo, Tomatis Mariano, Soerjomataram Isabelle, Primic Žakelj Maja, Dillner Joakim, Elfström Klara Miriam, Lönnberg Stefan, Sankaranarayanan Rengaswamy
Screening Group, International Agency for Research on Cancer, Lyon, France.
CPO Piemonte and University Hospital "Città della Salute e della Scienza", Turin, Italy.
Int J Cancer. 2018 Jan 1;142(1):44-56. doi: 10.1002/ijc.31043. Epub 2017 Oct 10.
The second report on the implementation status of cancer screening in European Union (EU) was published in 2017. The report described the implementation status, protocols and organization (updated till 2016) and invitation coverage (for index year 2013) of breast, cervical and colorectal cancer screening in the EU. Experts in screening programme monitoring (N = 80) from the EU Member States having access to requisite information in their respective countries provided data on breast, cervical and colorectal cancer screening through online questionnaires. Data was collected for screening performed in the framework of publicly mandated programmes only. Filled in questionnaires were received from 26 Member States for all three sites and from one Member State for breast cancer only. Substantial improvement in screening implementation using population-based approach was documented. Among the age-eligible women, 94.7% were residents of Member States implementing or planning population-based breast cancer screening in 2016, compared to 91.6% in 2007. The corresponding figures for cervical cancer screening were 72.3 and 51.3% in 2016 and 2007, respectively. Most significant improvement was documented for colorectal cancer screening with roll-out ongoing or completed in 17 Member States in 2016, compared to only five in 2007. So the access to population-based screening increased to 72.4% of the age-eligible populations in 2016 as opposed to only 42.6% in 2007. The invitation coverage was highly variable, ranging from 0.2-111% for breast cancer, 7.6-105% for cervical cancer and 1.8-127% for colorectal cancer in the target populations. In spite of the considerable progress, much work remains to be done to achieve optimal effectiveness. Continued monitoring, regular feedbacks and periodic reporting are needed to ensure the desired impacts of the programmes.
欧盟（EU）癌症筛查实施状况的第二份报告于2017年发布。该报告描述了欧盟乳腺癌、宫颈癌和结直肠癌筛查的实施状况、方案及组织情况（更新至2016年）以及邀请覆盖率（以2013年为指标年份）。来自欧盟成员国且能获取各自国家必要信息的筛查项目监测专家（N = 80）通过在线问卷提供了乳腺癌、宫颈癌和结直肠癌筛查的数据。仅收集了在公共强制项目框架内进行的筛查数据。收到了来自26个成员国关于所有三个部位的填写完整的问卷，以及来自一个成员国仅关于乳腺癌的问卷。记录显示，采用基于人群的方法在筛查实施方面有了显著改善。在符合年龄条件的女性中，2016年有94.7%是实施或计划进行基于人群乳腺癌筛查的成员国的居民，而2007年这一比例为91.6%。2016年和2007年宫颈癌筛查的相应数字分别为72.3%和51.3%。结直肠癌筛查取得了最显著的改善记录，2016年有17个成员国正在进行或已完成推广，而2007年仅有5个成员国。因此，2016年基于人群筛查的可及率提高到了符合年龄条件人群的72.4%，而2007年仅有42.6%。目标人群中邀请覆盖率差异很大，乳腺癌为0.2 - 111%，宫颈癌为7.6 - 105%，结直肠癌为1.8 - 127%。尽管取得了相当大的进展，但要实现最佳效果仍有许多工作要做。需要持续监测、定期反馈和定期报告，以确保这些项目能产生预期影响。
